InsidersTradesSigma
Follow the 지에프씨생명과학 share price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares are listed on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 지에프씨생명과학 has recorded 6 insider filings. Market capitalisation: €29.8bn. The latest transaction was filed on 10 April 2026 (Purchase). Among the most active insiders: 강희철. The full history is openly available.
6
Insider Decl.
n/a
Thresholds
€210,842
6 ops.
Buy Volume
n/a
n/a
Sell Volume
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,287 of 28,753 companies
35.4
score / 100
Value26
Quality45
FCF yld-20%
Earn yld1.8%
EV/EBITDA18.5x
ROE4.1%
Gross mgn48%
Net mgn3.1%
Debt/EBITDA3.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 10 April 2026
Declarations6 total
6 of 6 declarations
关于 지에프씨생명과학
지에프씨생명과학 是一家在健康和制药领域运营的公司，在 XKRX 市场上市。它专注于开发创新的医疗保健解决方案。